PolyNovo
PNV.ASXHealth Care
PolyNovo develops and commercialises innovative medical devices using its NovoSorb technology in the treatment of burns, surgical wounds and Negative Pressure Wound Therapy.
Market Data
$0.870
-0.1%$639.0M
64.7x
$0.014
0.00%
-0.3%
Latest Earnings
Appendix 4D & H1 FY26 Financial Statements
20 February 2026
PolyNovo delivered strong commercial growth with group sales up 26.0% to A$68.2m in H1 FY26, driven by 195.2% growth in NovoSorb MTX sales and expansion across all key markets. Net profit essentially flat at A$0.0m (vs A$3.3m prior year) due to reduced manufacturing output for PMA submission preparation and R&D laboratory fire impact, though EBITDA adjusted for significant items increased 82.0%. The company completed construction of its additional manufacturing facility and remains well-positioned for continued growth with multiple catalysts ahead. Key points: Strong commercial sales growth of 26.0% to A$68.2m with expansion across all key markets; NovoSorb MTX delivered exceptional 195.2% growth reaching A$6.2m in sales; U.S. market performance remained robust with 25.3% growth to A$51.7m
Recent Announcements
Ceasing to be a substantial holder
JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.
PolyNovo FY26 Trading Update
PolyNovo Limited reported FY26 revenue of AUD 150.0 million (up 16.1% year-on-year), with strong commercial sales growth of 16.7%, improved cash position, and completed manufacturing facility expansion, though full EBITDA and NPAT figures will be released on 26 August 2026.
Becoming a substantial holder
JPMorgan Chase & Co. and its affiliates became a substantial holder (5.13%).
Ceasing to be a substantial holder
JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.
Ceasing to be a substantial holder
State Street Corporation ceased to be a substantial holder.
Ceasing to be a substantial holder
UBS Group AG ceased to be a substantial holder.
Becoming a substantial holder
UBS Group AG became a substantial holder (5.42%).
Webcast Recording - 1H26 Financial Results
PolyNovo (ASX: PNV) has made available a webcast recording of its H1 FY26 financial results presentation, including updates from the Chair and CEO, financial results, and Q&A session for shareholders unable to attend the live event.
Appendix 4D & H1 FY26 Financial Statements
PolyNovo delivered strong commercial growth with group sales up 26.0% to A$68.2m in H1 FY26, driven by 195.2% growth in NovoSorb MTX sales and expansion across all key markets. Net profit essentially flat at A$0.0m (vs A$3.3m prior year) due to reduced manufacturing output for PMA submission preparation and R&D laboratory fire impact, though EBITDA adjusted for significant items increased 82.0%. The company completed construction of its additional manufacturing facility and remains well-positioned for continued growth with multiple catalysts ahead. Key points: Strong commercial sales growth of 26.0% to A$68.2m with expansion across all key markets; NovoSorb MTX delivered exceptional 195.2% growth reaching A$6.2m in sales; U.S. market performance remained robust with 25.3% growth to A$51.7m
Earnings Release - 26 August 2026
Upcoming earnings release expected 26 August 2026 (from Yahoo Finance (confirmed))
Get real-time alerts for PNV
Receive AI-powered earnings summaries and instant notifications when PolyNovo releases results.
Register Free